{"id":"https://openalex.org/W2039944287","doi":"https://doi.org/10.1111/j.1365-2141.2008.07378.x","title":"Bortezomib is associated with better health\u2010related quality of life than high\u2010dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study","display_name":"Bortezomib is associated with better health\u2010related quality of life than high\u2010dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study","publication_year":2008,"publication_date":"2008-10-02","ids":{"openalex":"https://openalex.org/W2039944287","doi":"https://doi.org/10.1111/j.1365-2141.2008.07378.x","mag":"2039944287","pmid":"https://pubmed.ncbi.nlm.nih.gov/18986387"},"language":"en","primary_location":{"id":"doi:10.1111/j.1365-2141.2008.07378.x","doi":"https://doi.org/10.1111/j.1365-2141.2008.07378.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1365-2141.2008.07378.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2141.2008.07378.x","source":{"id":"https://openalex.org/S153015021","display_name":"British Journal of Haematology","issn_l":"0007-1048","issn":["0007-1048","1365-2141"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Haematology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2141.2008.07378.x","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5031390636","display_name":"Stephanie Joi Lee","orcid":"https://orcid.org/0000-0003-2600-6390","observed_orcids":["https://orcid.org/0000-0003-2600-6390"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Stephanie J. Lee","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA. sjlee@fhcrc.org","Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA. sjlee@fhcrc.org","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043526996","display_name":"Paul Gerard Guy Richardson","orcid":"https://orcid.org/0000-0002-7426-8865","observed_orcids":["https://orcid.org/0000-0002-7426-8865"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul G. Richardson","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002972322","display_name":"Pieter Sonneveld","orcid":"https://orcid.org/0000-0002-0808-2237","observed_orcids":["https://orcid.org/0000-0002-0808-2237"]},"institutions":[{"id":"https://openalex.org/I2801952686","display_name":"Erasmus MC","ror":"https://ror.org/018906e22","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2801952686"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Pieter Sonneveld","raw_affiliation_strings":["University Hospital Rotterdam, Rotterdam, Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Hospital Rotterdam, Rotterdam, Netherlands","institution_ids":["https://openalex.org/I2801952686"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5106408675","display_name":"Michael W. Schuster","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1340179700","display_name":"NewYork\u2013Presbyterian Hospital","ror":"https://ror.org/03gzbrs57","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1340179700"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael W. Schuster","raw_affiliation_strings":["New York-Presbyterian Hospital, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"New York-Presbyterian Hospital, New York, NY","institution_ids":["https://openalex.org/I1340179700"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109801302","display_name":"David H. Irwin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David Irwin","raw_affiliation_strings":["Alta Bates Cancer Center, Berkeley, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alta Bates Cancer Center, Berkeley, CA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020989412","display_name":"Jes\u00fas F. San Miguel","orcid":"https://orcid.org/0000-0002-9183-4857","observed_orcids":["https://orcid.org/0000-0002-9183-4857"]},"institutions":[{"id":"https://openalex.org/I4210099034","display_name":"Complejo Hospitalario de Salamanca","ror":"https://ror.org/0131vfw26","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I184999862","https://openalex.org/I4210099034"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Jes\u00fas\u2010F. San Miguel","raw_affiliation_strings":["Hospital Universitario de Salamanca, Salamanca, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital Universitario de Salamanca, Salamanca, Spain","institution_ids":["https://openalex.org/I4210099034"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078326675","display_name":"Bruce Crawford","orcid":"https://orcid.org/0000-0001-9109-728X","observed_orcids":["https://orcid.org/0000-0001-9109-728X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bruce Crawford","raw_affiliation_strings":["Mapi Values, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mapi Values, Cambridge, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008596377","display_name":"Joseph M. Massaro","orcid":"https://orcid.org/0000-0002-2682-4812","observed_orcids":["https://orcid.org/0000-0002-2682-4812"]},"institutions":[{"id":"https://openalex.org/I111088046","display_name":"Boston University","ror":"https://ror.org/05qwgg493","country_code":"US","type":"education","lineage":["https://openalex.org/I111088046"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph Massaro","raw_affiliation_strings":["Boston University School of Public Health, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston University School of Public Health, Boston, MA","institution_ids":["https://openalex.org/I111088046"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079485616","display_name":"Ravinder Dhawan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ravinder Dhawan","raw_affiliation_strings":["Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100619365","display_name":"Sanjay Kumar Gupta","orcid":"https://orcid.org/0000-0001-9429-9805","observed_orcids":["https://orcid.org/0000-0001-9429-9805","https://orcid.org/0009-0002-9655-7032"]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sanjay Gupta","raw_affiliation_strings":["Millennium Pharmaceuticals, Inc., Cambridge, MA, USA","Present address: Sanjay Gupta, Abbott Laboratories"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Millennium Pharmaceuticals, Inc., Cambridge, MA, USA","institution_ids":["https://openalex.org/I4405270001"]},{"raw_affiliation_string":"Present address: Sanjay Gupta, Abbott Laboratories","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5032464400","display_name":"Kenneth Carl Anderson","orcid":"https://orcid.org/0000-0002-6418-0886","observed_orcids":["https://orcid.org/0000-0002-6418-0886"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth C. Anderson","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":7,"corresponding_author_ids":["https://openalex.org/A5031390636"],"corresponding_institution_ids":["https://openalex.org/I4210117453"],"apc_list":{"value":5190,"currency":"USD","value_usd":5190},"apc_paid":null,"fwci":2.9264,"has_fulltext":true,"cited_by_count":68,"citation_normalized_percentile":{"value":0.90963164,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"143","issue":"4","first_page":"511","last_page":"519"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9945999979972839,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9945999979972839,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10178","display_name":"Cancer survivorship and care","score":0.0027000000700354576,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/dexamethasone","display_name":"dexamethasone","score":0.953000009059906},{"id":"https://openalex.org/keywords/relapsed-multiple-myeloma","display_name":"relapsed multiple myeloma","score":0.9990000128746033},{"id":"https://openalex.org/keywords/health-related-quality-of-life","display_name":"health-related quality of life","score":0.9990000128746033},{"id":"https://openalex.org/keywords/apex-trial","display_name":"APEX trial","score":0.8579999804496765},{"id":"https://openalex.org/keywords/eortc-qlq-c30","display_name":"EORTC QLQ-C30","score":0.8140000104904175},{"id":"https://openalex.org/keywords/neurotoxicity","display_name":"neurotoxicity","score":0.875},{"id":"https://openalex.org/keywords/cognitive-function","display_name":"cognitive function","score":0.4909999966621399},{"id":"https://openalex.org/keywords/dyspnea","display_name":"dyspnea","score":0.7559999823570251},{"id":"https://openalex.org/keywords/sleep-symptoms","display_name":"sleep symptoms","score":0.6880000233650208},{"id":"https://openalex.org/keywords/survival","display_name":"survival","score":0.7409999966621399}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9075449705123901},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.9003856778144836},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.7410984039306641},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6594420075416565},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.6576335430145264},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.5828526020050049},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.46436071395874023},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.42471930384635925},{"id":"https://openalex.org/C159110408","wikidata":"https://www.wikidata.org/wiki/Q121176","display_name":"Nursing","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000069286","descriptor_name":"Bortezomib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001897","descriptor_name":"Boronic Acids","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003907","descriptor_name":"Dexamethasone","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004812","descriptor_name":"Epidemiologic Methods","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011788","descriptor_name":"Quality of Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D012008","descriptor_name":"Recurrence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1111/j.1365-2141.2008.07378.x","doi":"https://doi.org/10.1111/j.1365-2141.2008.07378.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1365-2141.2008.07378.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2141.2008.07378.x","source":{"id":"https://openalex.org/S153015021","display_name":"British Journal of Haematology","issn_l":"0007-1048","issn":["0007-1048","1365-2141"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Haematology","raw_type":"journal-article"},{"id":"pmid:18986387","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18986387","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of haematology","raw_type":"Journal Article"},{"id":"pmh:oai:pure.eur.nl:openaire_cris_publications/c316ba7f-39c3-4b9d-a0b9-0e10fe08b367","doi":null,"is_oa":false,"landing_page_url":"https://pure.eur.nl/en/publications/c316ba7f-39c3-4b9d-a0b9-0e10fe08b367","pdf_url":null,"source":{"id":"https://openalex.org/S4306401266","display_name":"EUR Research Repository (Erasmus University Rotterdam)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I913958620","host_organization_name":"Erasmus University Rotterdam","host_organization_lineage":["https://openalex.org/I913958620"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Lee, SJ, Richardson, PG, Sonneveld, P, Schuster, MW, Irwin, D, Miguel, JFS, Crawford, B, Massaro, J, Dhawan, R, Gupta, S & Anderson, KC 2008, 'Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study', British Journal of Haematology, vol. 143, no. 4, pp. 511-519. https://doi.org/10.1111/j.1365-2141.2008.07378.x","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:eur:oai:pure.eur.nl:publications/c316ba7f-39c3-4b9d-a0b9-0e10fe08b367","doi":null,"is_oa":false,"landing_page_url":"https://pure.eur.nl/en/publications/c316ba7f-39c3-4b9d-a0b9-0e10fe08b367","pdf_url":null,"source":{"id":"https://openalex.org/S4306401266","display_name":"EUR Research Repository (Erasmus University Rotterdam)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I913958620","host_organization_name":"Erasmus University Rotterdam","host_organization_lineage":["https://openalex.org/I913958620"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"British Journal of Haematology, 143(4), 511 - 519. Wiley-Blackwell Publishing Ltd","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1111/j.1365-2141.2008.07378.x","doi":"https://doi.org/10.1111/j.1365-2141.2008.07378.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1365-2141.2008.07378.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2141.2008.07378.x","source":{"id":"https://openalex.org/S153015021","display_name":"British Journal of Haematology","issn_l":"0007-1048","issn":["0007-1048","1365-2141"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Haematology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320320300","display_name":"European Commission","ror":"https://ror.org/00k4n6c32"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2039944287.pdf","grobid_xml":"https://content.openalex.org/works/W2039944287.grobid-xml"},"referenced_works_count":42,"referenced_works":["https://openalex.org/W139186542","https://openalex.org/W1931544110","https://openalex.org/W1976566530","https://openalex.org/W1980311540","https://openalex.org/W1982499121","https://openalex.org/W2002330540","https://openalex.org/W2002395765","https://openalex.org/W2011668576","https://openalex.org/W2023524284","https://openalex.org/W2028524875","https://openalex.org/W2036026045","https://openalex.org/W2053577305","https://openalex.org/W2066800926","https://openalex.org/W2073942227","https://openalex.org/W2078340902","https://openalex.org/W2093070779","https://openalex.org/W2093666912","https://openalex.org/W2096491215","https://openalex.org/W2102591890","https://openalex.org/W2107057207","https://openalex.org/W2108235071","https://openalex.org/W2110385671","https://openalex.org/W2110466835","https://openalex.org/W2111650326","https://openalex.org/W2115012618","https://openalex.org/W2118975628","https://openalex.org/W2124560610","https://openalex.org/W2130606506","https://openalex.org/W2139391294","https://openalex.org/W2145638852","https://openalex.org/W2152333590","https://openalex.org/W2160088903","https://openalex.org/W2167571044","https://openalex.org/W2169231929","https://openalex.org/W2472372483","https://openalex.org/W2556749292","https://openalex.org/W2560801473","https://openalex.org/W2599228863","https://openalex.org/W2601846828","https://openalex.org/W2979560099","https://openalex.org/W4232496617","https://openalex.org/W4236730981"],"related_works":["https://openalex.org/W2311454266","https://openalex.org/W2607384084","https://openalex.org/W2915197659","https://openalex.org/W2908410142","https://openalex.org/W2589057659","https://openalex.org/W3016169822","https://openalex.org/W7217835511","https://openalex.org/W2563483539","https://openalex.org/W2980298754","https://openalex.org/W4412461070"],"abstract_inverted_index":{"Health-related":[0],"quality":[1],"of":[2,14,30,34,43],"life":[3],"(HRQL)":[4],"was":[5,185],"prospectively":[6],"measured":[7],"during":[8],"the":[9,100,197],"phase":[10],"III":[11],"APEX":[12],"trial":[13],"bortezomib":[15,65,171,184],"versus":[16,102],"dexamethasone":[17,105],"in":[18],"relapsed":[19],"multiple":[20,151],"myeloma":[21],"patients.":[22],"The":[23],"European":[24],"Organisation":[25],"for":[26,74,85,113,121,155],"Research":[27],"and":[28,40,55,72,83,111,135,141,145],"Treatment":[29],"Cancer":[31,44],"(EORTC)":[32],"Quality":[33],"Life":[35],"Questionnaire":[36],"-":[37],"Core":[38],"(QLQ-C30)":[39],"Functional":[41],"Assessment":[42],"Therapy/Gynecologic":[45],"Oncology":[46],"Group-Neurotoxicity":[47],"(NTX)":[48],"side-effects":[49],"questionnaires":[50],"were":[51,159],"administered":[52],"at":[53,173],"baseline":[54],"every":[56],"6":[57],"weeks":[58],"up":[59],"to":[60,153],"42":[61],"weeks.":[62],"Patients":[63],"receiving":[64,104],"(1.3":[66],"mg/m(2),":[67],"days":[68,79,108,118],"1,":[69,80],"4,":[70],"8":[71],"11":[73],"eight":[75],"3-week":[76],"cycles,":[77,116],"then":[78,117],"8,":[81],"15":[82],"22":[84],"three":[86],"5-week":[87,115],"cycles;":[88,124],"n":[89,125],"=":[90,126],"296)":[91],"demonstrated":[92],"significantly":[93,129,188],"better":[94,130,146,189,198],"mean":[95],"Global":[96],"Health":[97],"Status":[98],"over":[99],"study":[101],"patients":[103],"(40":[106],"mg/d,":[107],"1-4,":[109],"9-12,":[110],"17-20":[112],"four":[114],"1-4":[119],"only":[120],"five":[122],"4-week":[123],"302),":[127],"plus":[128],"physical":[131],"health,":[132],"role,":[133],"cognitive,":[134],"emotional":[136],"functioning":[137],"scores,":[138,144],"lower":[139],"dyspnoea":[140],"sleep":[142],"symptom":[143],"NTX":[147],"questionnaire":[148],"score,":[149],"using":[150,161],"imputation":[152],"account":[154],"missing":[156],"data.":[157],"Results":[158],"similar":[160],"available-data":[162],"analyses.":[163],"Sensitivity":[164],"analyses":[165],"suggested":[166],"that":[167,183],"improved":[168,178],"HRQL":[169,191],"with":[170,187,193,196,202],"is":[172],"least":[174],"partially":[175],"explained":[176],"by":[177],"survival.":[179],"These":[180],"results":[181],"show":[182],"associated":[186],"multidimensional":[190],"compared":[192],"dexamethasone,":[194],"consistent":[195],"clinical":[199],"outcomes":[200],"seen":[201],"bortezomib.":[203]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":3},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":8},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":10}],"updated_date":"2026-11-02T09:45:03.842371","created_date":"2016-06-24T00:00:00"}